Loading...
XTAI
4142
Market cap238mUSD
Aug 28, Last price  
17.90TWD
Name

Adimmune Corp

Chart & performance

D1W1MN
XTAI:4142 chart
P/E
P/S
5.38
EPS
Div yield, %
Shrs. gr., 5y
0.52%
Rev. gr., 5y
-5.60%
Revenues
Net income
CFO
Dividend
Sep 14, 20210.5 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Adimmune Corporation, a Taiwanese pharmaceutical company, specializes in the production and distribution of human vaccines. Its comprehensive product portfolio includes a range of critical immunizations. Key offerings feature the quadrivalent influenza vaccine, AdimFlu-S, alongside trivalent influenza vaccines and the Influenza A (H1N1) Virus Monovalent Vaccine. The company also provides tetanus toxoid products, vital for post-injury tetanus prevention, and Japanese encephalitis vaccines. Furthermore, Adimmune supplies purified Tuberculin and extends its expertise through contract manufacturing services. Established in 1965, the company initially operated under the name Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. It subsequently rebranded as Adimmune Corporation in 2001 and maintains its headquarters in Taichung, Taiwan.
IPO date
Sep 29, 2010
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

No data to show